Methotrexate News and Research RSS Feed - Methotrexate News and Research

Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Research unlocks potential new therapies for inflammatory diseases

Research unlocks potential new therapies for inflammatory diseases

Macrophages are frontline cells in our immune system. They detect microbial invaders and also tissue injury and then mount an appropriate response needed to clear the infection and repair the damaged tissue. [More]
Over-the-counter and prescription pain medications linked to drug-induced liver injury

Over-the-counter and prescription pain medications linked to drug-induced liver injury

More than 1,000 medications, with acetaminophen being the most common, have been associated with drug-induced liver injury. [More]
Smoking, excess weight may influence how rheumatoid arthritis symptoms improve with treatment

Smoking, excess weight may influence how rheumatoid arthritis symptoms improve with treatment

A study finds that smoking or being overweight makes it more difficult for patients with rheumatoid arthritis to achieve optimal control of inflammation and symptoms, despite standard of care treatment. [More]
CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy, and patient-centered research, today announced the forthcoming publication of “A Patient’s Guide to Living with Rheumatoid Arthritis.” [More]
FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. [More]
Scientists discover genomic alterations in pediatric relapsed ALL

Scientists discover genomic alterations in pediatric relapsed ALL

A group of researchers from Columbia University, Rutgers University, and institutions in Europe and Japan have identified genomic alterations in pediatric relapsed acute lymphoblastic leukemia (ALL) that cause both therapy resistance and improved clinical response to multi-agent chemotherapy treatment. [More]
Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs. [More]
Penn State dermatologist clarifies common myths about psoriasis

Penn State dermatologist clarifies common myths about psoriasis

Psoriasis is a much-misunderstood disease, often kept under wraps by sufferers who want to hide their skin lesions. [More]
Psoriasis treatments may help improve cardiovascular symptoms by reducing skin inflammation

Psoriasis treatments may help improve cardiovascular symptoms by reducing skin inflammation

Approximately 7.5 million people in the United States have psoriasis, and the impact of this disease goes far beyond its visible effects on the skin. [More]
Immunotherapy-treated cancer patients may develop rheumatic disorders

Immunotherapy-treated cancer patients may develop rheumatic disorders

Oncologists need to be aware of the potential for rheumatological diseases in patients with cancer following treatment with immune checkpoint inhibitors, say US investigators. [More]
Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a range of factors other than just cost may influence the prescribing of TNF inhibitors for patients with rheumatoid arthritis (RA). [More]
Study sheds light on why many RA patients do not adhere to treatment

Study sheds light on why many RA patients do not adhere to treatment

Two new studies presented at the European League Against Rheumatism Annual Congress have shed light on why so many patients with Rheumatoid Arthritis (RA) do not adhere to their therapy, even in the early stages of their treatment. [More]
Smoking, obesity lower chances of achieving sustained remission in early RA patients

Smoking, obesity lower chances of achieving sustained remission in early RA patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that the likelihood of achieving sustained remission in early rheumatoid arthritis (RA) is significantly lower in patients who smoke and who are obese. [More]
BNPs have potential to enable early diagnosis, long-term treatment of RA with minimal side effects

BNPs have potential to enable early diagnosis, long-term treatment of RA with minimal side effects

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that tiny particles made of a biodegradable polymer (BNPs -- biodegradable polymer nanoparticles) have the potential to enable early detection and efficient long-term treatment of rheumatoid arthritis (RA), with minimal side effects. [More]
Study finds differences in hospitalization trends for gout and rheumatoid arthritis

Study finds differences in hospitalization trends for gout and rheumatoid arthritis

While hospitalizations related to rheumatoid arthritis have dropped considerably over the past two decades, hospitalizations primarily associated with gout have increased dramatically. [More]
Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting. [More]
Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with mental flexibility, organization and related skills as long-term survivors. [More]
High doses of commonly-used chemotherapy drug may increase survival rate of ALL patients

High doses of commonly-used chemotherapy drug may increase survival rate of ALL patients

With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients. [More]
Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. [More]
Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24. [More]
Advertisement
Advertisement